Treatment of Relapsed CLL - Webinar: Whilst we... - CLL Support

CLL Support

22,609 members38,830 posts

Treatment of Relapsed CLL - Webinar

Jm954 profile image
Jm954Administrator
4 Replies

Whilst we worry about starting treatment for the first time, there are plenty of treatment choices potentially available to us. However, for those navigating treatment for relapsed disease the picture is often more complex and with less options available.

On 6 December 2022, CLLAN (CLL Advocates Network) hosted a webinar on “CLL treatment in the relapsed-refractory setting and promising therapeutic approaches to fulfil unmet needs”.

This educational session discussed advances in how relapsed/refractory CLL patients and those who fail a treatment are treated today. What therapies are used for subsequent treatments and what promising new developments may fulfil unmet treatment needs?

Here's the link -

clladvocates.net/cllan-webi... 

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
4 Replies
mrsjsmith profile image
mrsjsmith

Thanks Jackie,

I watched it and found it very interesting, but most importantly it was understandable. Sometimes I get lost with technical jargon.

Colette

Justasheet1 profile image
Justasheet1

Thanks Jackie, loved it too.

Jeff

MN1999 profile image
MN1999

Could you do a brief synopsis of the findings? I couldn't bring up the volume enough to hear the speakers.

TeamDirtyBoots profile image
TeamDirtyBoots

Thanks! I agree with the other comments, very helpful.

You may also like...

Webinar on CLL treatment - a Changing Landscape

for a webinar by our sister charity Leukaemia Care on chronic lymphocytic leukaemia (CLL)...

UK webinar - CLL treatment a changing landscape

Join us for an upcoming webinar on chronic lymphocytic leukaemia (CLL) treatment. Register here...

Relapse/Refractory CLL

com/cllsupport/posts/148876799/treatment-of-relapsed-cll-webinar In part of this video, they...

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

care for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have progressed on

CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)

com/view/dr-kenderian-on-the-fda-approval-of-liso-cel-in-relapsed-refractory-cll-sll